Best Clinical Genomics Companies in Florida, United States
The 31 best Clinical Genomics companies in Florida, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: NeoGenomics.
Ranked: Best Clinical Genomics companies in Florida
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NeoGenomics Provider of cancer genetic diagnostic services | $446M | 69 mo ago | Public | — | 2002 | SentryBugHerdApple iCloud Mail+20 | — | — |
| 2 | PositiveID Corporation Developer of biological detection and diagnostics solutions | $11M | 165 mo ago | Deadpooled | — | 2001 | — | 4 patents Real-time wireless acetone gas sensing for breath/industrial monitoring | — |
| 3 | VuEssence Genome based diagnostic technology platform | $3M | 18 mo ago | Seed | Maha Sallam Founder & President | 2010 | — | 2 patents Patents concentrated in health & consumer products | — |
| 4 | MDNA Life Sciences Provider of genomic and molecular diagnostics based on the mitochondrial genome | $1M | 93 mo ago | Acquired | — | 2001 | — | — | — |
| 5 | Cvergenx Genomic informatics company personalizing radiation therapy with precision genomic radiation therapy platform | $616K | 130 mo ago | Seed | — | 2009 | — | 10 patents Genomics-driven personalized radiation dosing for head‑and‑neck cancer treatment | — |
| 6 | GeneLink BioSciences Genome-based nutritional supplements | $105K | 163 mo ago | Public | Robert Ricciardi Founder | 1994 | — | — | — |
| 7 | ProCare Diagnostics Developer of next-generation diagnostic tests for prostate cancer | $58K | 121 mo ago | Seed | Navroze Mehta Founder & CEO | 2015 | — | — | — |
| 8 | Ajuvis Labs Provider of microbiome therapies and interventions for healthcare | — | — | Unfunded | Howard Weiss Co-Founder | 2016 | — | — | — |
Top 7 Clinical Genomics companies in Florida
#1
Seed · Tampa, Florida · founded 2010 · 5 employees$2.7Mraised▾
VuEssence is developing diagnostic technology platforms for the treatment of stroke and neurological conditions. The company is developing diagnostic devices which use molecular analysis based on human genome and transcriptome data for the detection and management of stroke.
- Apr 2025Seed$47.5K
- Mar 2018Seed$1.5M
- May 2016Seed$1.2M
#2
Public · Fort Myers, Florida · founded 2002 · 2100 employees$445.5Mraised▾
Provider of cancer genetic diagnostic services. The company operates a network of cancer-focused testing labs, which is engaged in providing testing services to pathologists, oncologists, and other laboratories. The company provides services for cancer cytogenetics, hematologic and solid tumor FISH testing, 10-color flow cytometry, and nearly 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry.
- Jan 2021Post IPO$345M
- Jun 2019Conventional Debt$100M
- Mar 2009Post IPO$500K
#3
Deadpooled · Delray Beach, Florida · founded 2001 · 30 employees$10.9Mraised▾
Developer of biological detection and diagnostics solutions. The company focused on the development of microfluidic systems M-BAND (Microfluidic Bio-agent Autonomous Networked Detector) that analyzes air samples for the detection of biological airborne threats in the form of bacteria, viruses, and toxins.
- Jan 2013Series A$1.1M
- Aug 2011Series A$1.5M
- May 2011Series A$950K
- Mar 2011Series A$4.7M
#4
Acquired · Jupiter, Florida · founded 2001 · 8 employees$1.2Mraised▾
Provider of genomic and molecular diagnostics based on the mitochondrial genome. The company develops assays for oncology, including skin, breast, prostate, and lung cancers. The flagship product Prostate Core Mitomic Test identifies men at high risk of having a prostate tumor without the need for further invasive biopsy procedures. The company has tests for endometriosis, ovarian cancer, lung cancer, and pancreatic cancer.
- Jan 2019Seed$470K
- Feb 2018Seed$227.5K
- May 2017Seed$410.1K
- Jun 2015Seed$100K
#5
Seed · Tampa, Florida · founded 2009 · 3 employees$615.6Kraised▾
Genomic informatics company personalizing radiation therapy with precision genomic radiation therapy platform. This innovative technology provides decision-support for radiation oncologists to optimize radiation therapy for each patient. The Precision Genomic Radiation Therapy platform (pGRT) utilizes tumor-specific genomic data to quantify the personalized biological effect of radiation therapy. It integrates a gene expression signature of tumor radiosensitivity (RSI) into a model to quantify the genomic-adjusted radiation dose (GARD), representing a predicted personalized biologic radiation effect. Radiation oncologists can utilize GARD to optimize the therapeutic index of a radiation therapy plan, maximizing the biological effect on a tumor while respecting normal tissue dose constraints and safety guidelines. This offers the first opportunity for genomic-based radiation oncology, integrating biological information into radiotherapy treatment plans to optimize dose on an individualized basis. This approach brings precision medicine to radiation oncology by enabling clinicians to personalize and optimize radiation therapy dose to match a tumor’s biology and genomic differences.
- Dec 2015Seed$390K
- Apr 2010Seed$225.6K
#6
Public · Orlando, Florida · founded 1994 · 15 employees$105Kraised▾
GeneLink Biosciences provides customized nutritional supplements based on the person's genome. It uses next-generation sequencing to look at a panel of 12 key genes that have been correlated with nutrition. It then uses the results to make NGx custom nutritional supplements. Nutritionists can either order the genomic service in isolation or in combination with the customized nutritional supplements.
- Apr 2013Post IPO$50K
- Dec 2010Post IPO$465K
- Feb 2010Post IPO$150K
- Nov 2009Post IPO$260.5K
#7
Seed · Boca Raton, Florida · founded 2015$58Kraised▾
Developer of next-generation diagnostic tests for prostate cancer. The flagship urine-based test uses PCADM-1 as a biomarker to detect prostate cancer. The company claims that its test can prevent unnecessary biopsies and prostatectomies, and improve prognosis. It has both a lab-based assay as well as a point-of-care lateral flow assay.
- Oct 2016Seed$58K
- Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Clinical Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding flat · growth rising
How research on Diagnostics in Florida is moving
A read on the academic research around Diagnostics in Florida — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 211 papers.
- University of Florida54
- Mayo Clinic in Florida53
- Florida International University21
- University of South Florida19
- Florida College17
- Point-of-care testing3→7
- Liquid biopsy1→5
- Point of care3→4
- Liquid biopsy3→37
- Oncology1→12
- Internal medicine1→10
- Concordance1→7
- Circulating tumor cell3→8
- Point-of-care testing15
- Liquid biopsy14
- Biopsy6
- Point of care6
- Circulating tumor DNA5
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.